Palmerston North Hospital Regional Cancer Treatment Service - Clinical Trials

MidCentral District Health Board

B-Cell Chronic Lymphocytic Leukemia

Leukemia

Lymphoid Leukemia

Preleukemia

Syndrome

Myelodysplastic Syndromes

Magrolimab

Obinutuzumab

Azacitidine

Chlorambucil

Gilead Sciences

Roche

condition

allSponsorName

AbbVie

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years.

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

MidCentral District Health Board | Palmerston North Hospital Regional Cancer Treatment Service - Clinical Trials

Site insights

Work at this site?

Active trials

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Trial sponsors